A recent study examining data from over 2 million patients revealed that individuals with type 2 diabetes taking glucagon-like peptide-1 receptor agonists (GLP-1 RAs) face a heightened risk of developing chronic cough compared to those on other diabetes medications. Led by Dr. Tyler J. Gallagher, this retrospective analysis used records from 70 U.S. healthcare organizations. Findings emphasized the need for healthcare providers to recognize this potential side effect and manage symptoms accordingly, particularly for those without gastrointestinal symptoms, as chronic cough may indicate gastroesophageal reflux disease.
1. Study examines over 2 million patients with type 2 diabetes. 2. Increased chronic cough risk associated with GLP-1 RAs. 3. Long-acting GLP-1 RAs showed stronger association with cough. 4. Potential link: activation of the vagal nerve. 5. GERD may present as chronic cough without typical GI symptoms. 6. Management should consider reflux treatment for cough. 7. Acknowledges limitations such as lack of cough severity measures. 8. No conflicts of interest reported by researchers.
Listen Tab content
